MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Veracyte Inc. (NASDAQ:VCYT)*
Organization & Developments: Veracyte
Indivior
Parents
Veracyte Inc. (NASDAQ:VCYT)*
Children
*Developing minimally invasive molecular tests to provide earlier cancer diagnoses.
*Genomic tests for diagnosing cancers.
2018: Veracycte_Why this $6 Diagnostic Play is a Buy
2018: Veracyte, Loxo Oncology Partner on Drug Development Research
2019: Veracyte Finds Ally in J&J for Early Lung Cancer Detection
2019: Veracyte: Exceeding Expectations In Genomic Testing_seekingalpha.com
2020: Veracyte: A Strong Recovery Turning Into Strong Growth In The Midst Of A Pandemic
2022: Veracyte, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Veracyte: Sustainable Rally Supported By Spectacular Execution In Q3_ seekingalpha.com
2022: Veracyte: The FDA Is Stepping In_seekingalpha.com
2023: Nasal Swab Test Separates High- from Low-Risk Lung Cancer Polyps
2023: Veracyte's Strategic Growth Amid Volatility And Evolution In Genomic Diagnostics_ seekingalpha.com
2024: New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
2024: Veracyte, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Veracyte: Getting Frothy
2024: Why Veracyte, With 55% Growth In 2024, Is An Outlier In Cancer Diagnostics
2025: Veracyte: Upgrading To Neutral
Jumps
*Key People: Veracyte
Finance & Acquisition: Veracyte